Mereo BioPharma(US:MREO) Globenewswire·2026-02-14 12:14Core Viewpoint - Mereo BioPharma Group plc is facing potential legal claims due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and has set an April 6, 2026 deadline for investors to seek the role of lead plaintiff in a federal securities class action [2]. - The firm encourages investors who suffered losses in Mereo to contact them directly to discuss their legal options [1][8]. Group 2: Clinical Trial Results - Mereo announced that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the primary endpoint failures, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, a decline of 87.64%, closing at $0.28 per share on December 29, 2025 [6].